Dear Colleagues,

Cardiovascular disease (CVD), which includes coronary heart disease, heart failure (HF), valvular heart disease, congenital heart disease, rhythm disorders, cardiomyopathies, peripheral artery disease and arrhythmias,  remains a major challenge influencing the quality of care of patients and the economic global burden.

For patients suffering from CVD, several evidence-based treatments have remarkably improved the outcome; however, despite the best care, the percentage of undiagnosed or undertreated cases remains high.

It has been well-assessed that coronary artery disease (CAD) is one of the most significant causes of morbidity and mortality worldwide. CAD is characterized by atherosclerotic plaque accumulation in the epicardial arteries, which causes obstructive or non-obstructive disease. Various clinical presentations have been reported. However, acute coronary syndrome (ACS) or chronic coronary syndromes (CCS) are the leading forms of CAD. Long, stable periods followed by unstable phases are likely to occur typically due to acute atherothrombotic events caused by plaque rupture or erosion in ischemic patients.

Although patients with ACS have recently been provided with more advanced strategies due to the innovations in revascularization and pharmacological approaches, a high long-term risk of cardiovascular events remains in ACS. Accurate risk stratification of patients plays a crucial role in preventing long-term ischemic events.

HF is a syndrome consisting of acute or chronic symptoms (with reduced ejection fraction (HFrEF), with mildly reduced ejection fraction (HFmrEF), and with preserved ejection fraction (HFpEF)). Heart failure often complicates the treatment of cancer. Moreover, cardiovascular (CV) toxicities of most of cancer therapies have been reported. The cardio-oncology field has rapidly grown in the last few years.

Cardiomyopathies are myocardial disorders in which the muscles are structurally and/or functionally abnormal with a wide range of myocardial phenotypes or genotypes.

The aim of this Special Issue is to address the more debated aspect of lifestyle adjustments, the most innovative pharmacological therapies, and invasive interventions in contributing to obtaining CVD stabilization or regression.

Dr. Carmelo Massimiliano Rao
Dr. Iris Parrini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• coronary heart disease
• heart failure
• valvular heart disease
• congenital heart disease
• rhythm disorders
• cardiomyopathies
• peripheral artery disease
• arrhythmias